MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

2.03 -0.49

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

2.13

Schlüsselkennzahlen
By Trading Economics
Angestellte	26

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.6M 16M
Vorheriger Eröffnungskurs	2.52
Vorheriger Schlusskurs	2.03

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2026, 19:05 UTC

Wichtige Markttreiber

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. Jan. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. Jan. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Jan. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. Jan. 2026, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. Jan. 2026, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. Jan. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. Jan. 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. Jan. 2026, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. Jan. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. Jan. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. Jan. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. Jan. 2026, 19:03 UTC

Ergebnisse

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. Jan. 2026, 18:50 UTC

Ergebnisse

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. Jan. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. Jan. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. Jan. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. Jan. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.